OptiBiotix Health plc (LON:OPTI) said it plans to create a majority-owned joint-venture (JV) with the Healthy Weight Loss Company following a successful pilot launch of slimming products containing its Slimbiome ingredients.
The JV will be used as an “incubator” for the technology to develop other functional foods that help tackle obesity.
Having commercial sales will undoubtedly also help when it comes to talking to potential international partners that could help to further exploit the OptiBiotix technology.
Independent tests have revealed the component elements of Slimbiome reduced calorie intake by more than 20% as well as helping with cravings.
The test launch used them in snacks and shakes called GoFigure.
The new JV will have products on the shelves of unnamed retailers from August and “wider discussions are taking place”.
Meanwhile, early web-based sales are “outperforming expectations” with its range receiving positive reviews and “most importantly, dieters are finding the real benefits of this diet plan”, the company revealed.
Watch: Optibiotix's chief says company has made good progress in 2015
In-depth: OptiBiotix has high metabolism
Chief executive Stephen O’Hara said: "We are really pleased at the results from the trial and early consumer feedback which provides market evidence for the efficacy of Slimbiome in reducing calorie intake and managing weight loss which will help leverage discussions with international partners on use of Slimbiome as a supplement and food and dairy ingredient.
“We are delighted to partner with the management of The Healthy Weight Loss Company who have extensive experience in the weight management sector.
“This partnership creates a platform to take our technology developments to market on an accelerated basis providing early consumer feedback which will use to develop future product opportunities both nationally and on a global basis."
OptiBiotix is developing a range of products and additives that help manipulate the human microbiome to tackle obesity, high cholesterol and diabetes.